Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

17. september 2019 opdateret af: Lin Lu, Sun Yat-sen University

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy: A Prospective Randomized Multicenter Study

The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Recently, it's reported that intravitreal high dose Lucentis®（Ranibizumab） could benefit to both regression of the polyps and the relief of macular edema in PCV patients. Since it was a single arm prospective study with a relatively small sample size, randomized clinical trials were needed to confirm the efficacy of high dose Ranibizumab in PCV treatment. In this study, the investigator will compare the efficacy of double-dose (1mg, 3+prn) Raibizumab with regular dose (0.5mg, 3+prn) for PCV treatment.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

5

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Kina
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510060
        • Zhongshan Ophthalmic Center Guangzhou
      • Shenzhen, Guangdong, Kina, 518040
        • Retina surgery department, Shenzhen Eye Hospital of Second Clinical Medical College of Jinan University
    • Jiangsu
      • Xuzhou, Jiangsu, Kina, 221002
        • The First People's Hospital of Xuzhou
    • Shanghai
      • Shanghai, Shanghai, Kina, 201100
        • Dept. of Ophthalmology，Minhang hospital, Fudan University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 50 years and ≤80;
  • Active PCV confirmed by ICGA+FFA (Indocyanine green angiography + fundus fluorescein angiography);
  • At least one distinguishable polyp was shown in ICGA;
  • BCVA between 24 to 73 letters with ETDRS chart (Early Treatment of Diabetic Retinopathty Study);
  • The greatest linear dimension of the lesion <5400μm.

Exclusion Criteria:

  • Previously received treatment of laser retina photocoagulation, transpupillary thermotherapy, pneumatic displacement of subretinal blood or any investigational treatment;
  • Previous photodynamic therapy or anti-Vegf treatment within 6 months in study eye
  • Previously received treatment of photodynamic treatment within 1 month, or any anti-vascular endothelial growth factor (VEGF) intraocular injection in 3 months in the fellow eye;
  • Combine of current vitreous hemorrhage or extensive subretinal hemorrhage (lesion area >30mm2);
  • A history of angioid streaks, presumed ocular histoplasmosis syndrome or pathologic myopia;
  • Experienced retinal pigmental epithelium (RPE) tear, retinal detachment, macular hole or uncontrolled glaucoma;
  • Undergone intraocular surgery (except uncomplicated cataract extraction with intraocular lens implantation);
  • Cataract extraction with intraocular lens implantation within 60 days;
  • Combine of cataract that could require medical or surgical intervention during 12 months;
  • Combine of diabetes mellitus and have poor glucose control (Haemoglobin A1c (HbA1c) >8%);
  • Combine of hypertension and have poor blood pressure control (blood pressure ≥140/95 mmHg after regular antihypertensive drugs treatment);
  • History of myocardial infarction or cerebral infarction in last 6 months;
  • During gestation period or lactation period;
  • Combine of confirmed systemic autoimmune disease or any uncontrollable clinical conditions (e.g. HIV, malignant tumor, active hepatitis, severe systemic disease, diseases need immediately surgical treatment).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: double-dose

double-dose

Lucentis® (Raibizumab), 1mg, 3+prn
Medicin: Lucentis® (Raibizumab) double-dose
Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
Aktiv komparator: regular-dose

regular-dose

Lucentis® (Raibizumab), 0.5mg, 3+prn
Medicin: Lucentis® (Raibizumab) regular-dose
Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants who have at least 1 polyp resolution
Tidsramme: 6 months
Number of participants who have at least 1 polyp resolution, assessed by Indocyanine angiography (ICGA) between baseline and Month 6
6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
change of best corrected visual acuity(BCVA)
Tidsramme: Baseline to 6 months
Mean change in BCVA, from baseline to the end of 6 month. As assessed by changes of number of letters with the ETDRS (Early Treatment of Diabetic Retinopathy Study) chart
Baseline to 6 months
change of central foveal thickness
Tidsramme: Baseline to 6 months
Mean change of central foveal thickness, from baseline to the end of 6 month. As assessed by optical coherence tomography scanning
Baseline to 6 months
Injection frequency
Tidsramme: Baseline to 6 months
Average injection number(from baseline to the end of 6 month), assessed by the number of intravitreal injection from baseline to month 6
Baseline to 6 months
Safety analysis: number of adverse event
Tidsramme: 6 months
Serious ocular adverse events in the study eye, including reduced VA, retinal hemorrhage, endophthalmitis, corneal edema, iridocyclitis, macular degeneration, retinal artery occlusion, retinal tear, retinal vein occlusion and vitreous floaters. Antiplatelet Trialists' Collaboration (APTC) arterial thromboembolic events (ATEs): including deaths (vascular or unknown cause), nonfatal myocardial infarction and hemorrhagic or ischemic nonfatal cerebrovascular accident. Serious adverse event of special interest, including ATE, bleeding/hemorrhage in central nervous system (CNS) or non-CNS, congestive heart failure, fistulae, gastrointestinal perforation, hypertension, venous thrombotic events and wound healing complications.
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sun Yat-sen University

Efterforskere

  • Ledende efterforsker: Lin Lu, MD, phD, Zhongshan Ophthalmic Center Guangzhou, Guangdong China

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. august 2018

Primær færdiggørelse (Faktiske)

12. september 2018

Studieafslutning (Faktiske)

15. december 2018

Datoer for studieregistrering

Først indsendt

1. maj 2016

Først indsendt, der opfyldte QC-kriterier

8. maj 2016

Først opslået (Skøn)

11. maj 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. september 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. september 2019

Sidst verificeret

1. september 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • DREAM STUDY (Pear Therapeutics)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Polypoid choroidal vaskulopati

Kliniske forsøg med Lucentis® (Raibizumab) double-dose

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Austria

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner